Ascentage Pharma Group International (FRA:36X)

Market Cap	1.32B -61.7%
Revenue (ttm)	82.81M +64.5%
Net Income	-189.25M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.640
Previous Close	3.380
Day's Range	3.340 - 3.640
52-Week Range	0.845 - 9.100
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About FRA:36X

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 828
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 36X

Financial Performance

In 2025, FRA:36X's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error